Fuse Biotherapeutics Market Research Report
Company Overview
- Name: Fuse Biotherapeutics, Inc.
- Mission: Dedicated to developing transformative immune modulating therapeutics for patients with cancers. Their approach integrates multiple steps of an immune response rationally, targeting potent responses to danger while sparing healthy tissues.
- Founded: 2021
- Founders: Jeffrey Takimoto (Co-Founder and CEO), Brian Rabinovich (Co-Founder & CSO)
- Key People:
- Jeffrey Takimoto, Co-Founder and CEO
- Brian Rabinovich, Co-Founder & CSO
- Headquarters: Los Angeles, CA, US
- Number of Employees: 2-10 employees
- Revenue: No information is available.
- Specialties: Drug discovery, immunoncology, immunology, cancer treatment, NK cell biology, T cell biology, antibodies, and protein engineering.
- Website: [https://www.fusebiotx.com](https://www.fusebiotx.com)
- Company Type: Privately Held
- Known For: Developing immune modulating therapeutics for cancer treatment.
Products
- Products Offered:
- Targeted IL-18 platform
- High-Level Description:
- The targeted IL-18 platform is designed to combat terminal exhaustion and enhance the activity of cytotoxic lymphocytes.
- Key Features:
- Opposes terminal exhaustion
- Augments the activity of cytotoxic lymphocytes
Recent Developments
- Recent Developments:
- Presented a poster at the #AACR24 Annual Meeting showcasing the targeted IL-18 platform.
- New Products Launched: No information is available.
- New Features Added to Existing Products: No information is available.
- New Partnerships: No information is available.
Funding
- Total Funding Rounds: 1
- Last Funding Round: Seed round on December 15, 2021
- Amount Raised in Last Round: US$ 9.5M
- Investors: Viva BioInnovator plus 3 other investors
No additional commentary is included as per the instructions. This concludes the structured and information-dense market research report on Fuse Biotherapeutics.
